CN105451740B - 用纳曲酮治疗癌症 - Google Patents

用纳曲酮治疗癌症 Download PDF

Info

Publication number
CN105451740B
CN105451740B CN201480033900.4A CN201480033900A CN105451740B CN 105451740 B CN105451740 B CN 105451740B CN 201480033900 A CN201480033900 A CN 201480033900A CN 105451740 B CN105451740 B CN 105451740B
Authority
CN
China
Prior art keywords
tlr9
naltrexone
cancer
cells
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480033900.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN105451740A (zh
Inventor
安格斯·达格利什
蕾切尔·艾伦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ldn Pharmaceutical Co ltd
Original Assignee
CANCER VACCINE INSTITUTE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CANCER VACCINE INSTITUTE filed Critical CANCER VACCINE INSTITUTE
Publication of CN105451740A publication Critical patent/CN105451740A/zh
Application granted granted Critical
Publication of CN105451740B publication Critical patent/CN105451740B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201480033900.4A 2013-05-10 2014-05-12 用纳曲酮治疗癌症 Active CN105451740B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1308440.5 2013-05-10
GB201308440A GB201308440D0 (en) 2013-05-10 2013-05-10 Therapeutic
PCT/GB2014/051439 WO2014181131A1 (en) 2013-05-10 2014-05-12 Treatment of cancer with naltrexone

Publications (2)

Publication Number Publication Date
CN105451740A CN105451740A (zh) 2016-03-30
CN105451740B true CN105451740B (zh) 2019-07-19

Family

ID=48672126

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480033900.4A Active CN105451740B (zh) 2013-05-10 2014-05-12 用纳曲酮治疗癌症

Country Status (13)

Country Link
US (4) US9895438B2 (enExample)
EP (1) EP2994137B1 (enExample)
JP (1) JP6346269B2 (enExample)
KR (1) KR102162038B1 (enExample)
CN (1) CN105451740B (enExample)
AU (1) AU2014264445B2 (enExample)
BR (1) BR112015028269A2 (enExample)
CA (1) CA2912203C (enExample)
GB (1) GB201308440D0 (enExample)
IL (1) IL242533B (enExample)
MX (1) MX2015015582A (enExample)
RU (1) RU2686325C2 (enExample)
WO (1) WO2014181131A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201410216D0 (en) * 2014-06-09 2014-07-23 Cancer Vaccine Inst Therapeutic
GB201704911D0 (en) * 2017-03-28 2017-05-10 Ldn Pharma Ltd High dose combo I
CN111050801B (zh) * 2017-03-28 2023-03-28 Ldn制药有限公司 用于治疗癌症的增加bcl2-相关的细胞死亡激动剂表达的药剂
WO2019055597A1 (en) * 2017-09-13 2019-03-21 National Tuberous Sclerosis Association, Inc. Methods and compositions for the treatment of tsc
CA3113895A1 (en) * 2018-11-01 2020-05-07 Faron Pharmaceuticals Oy Tlr9 agonists for use in downregulating clever-1 expression on alternatively activated macrophages
WO2020178446A1 (en) * 2019-03-06 2020-09-10 LDN Pharma Limited Method of monitoring treatment
GB201903546D0 (en) * 2019-03-15 2019-05-01 Ldn Pharma Ltd Cancer treatment
AU2022211609A1 (en) * 2021-01-25 2023-07-27 LDN Pharma Limited Naltrexone compositions
CN114836529B (zh) * 2022-03-30 2023-05-30 唐颢 Ogfr基因或其编码的蛋白在心肌损伤辅助诊断及治疗中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6384044B1 (en) * 1999-11-29 2002-05-07 Bernard Bihari Method of treating cancer of the prostate

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4689332A (en) * 1984-04-09 1987-08-25 Research Corporation Growth regulation and related applications of opioid antagonists
GB8728294D0 (en) * 1987-12-03 1988-01-06 Reckitt & Colmann Prod Ltd Treatment compositions
US6136780A (en) * 1996-03-29 2000-10-24 The Penn State Research Foundation Control of cancer growth through the interaction of [Met5 ]-enkephalin and the zeta (ζ) receptor
EP0945133A1 (en) * 1998-03-26 1999-09-29 Lipha Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a NMDA receptor complex modulator
US6288074B1 (en) * 1998-11-17 2001-09-11 Bernard Bihari Method of treating lymphoproliferative syndrome
US6194382B1 (en) * 1999-03-03 2001-02-27 Albert Einstein College Of Medicine Of Yeshiva University Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists
CN103405431B (zh) * 2002-05-17 2016-04-13 台湾J药品有限公司 阿片和阿片样化合物及其用途
US8017622B2 (en) * 2003-05-16 2011-09-13 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
GB0509052D0 (en) 2005-05-04 2005-06-08 Aimsco Ltd Combination therapy
US20090191185A1 (en) * 2006-04-26 2009-07-30 The Uab Research Foundation Reducing Cancer Cell Invasion Using an Inhibitor of Toll Like Receptor Signaling
WO2011009015A1 (en) * 2009-07-16 2011-01-20 Mallinckrodt Inc. (+) - morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof
EP2593095B1 (en) 2010-07-16 2019-03-27 Mallinckrodt LLC (+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof
GB201410216D0 (en) * 2014-06-09 2014-07-23 Cancer Vaccine Inst Therapeutic
GB201704909D0 (en) * 2017-03-28 2017-05-10 Ldn Pharma Ltd Cancer therapy
GB201704911D0 (en) * 2017-03-28 2017-05-10 Ldn Pharma Ltd High dose combo I

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6384044B1 (en) * 1999-11-29 2002-05-07 Bernard Bihari Method of treating cancer of the prostate

Also Published As

Publication number Publication date
CA2912203A1 (en) 2014-11-13
EP2994137A1 (en) 2016-03-16
GB201308440D0 (en) 2013-06-19
US20220040295A1 (en) 2022-02-10
BR112015028269A2 (pt) 2017-07-25
IL242533B (en) 2020-10-29
WO2014181131A1 (en) 2014-11-13
NZ714999A (en) 2021-05-28
AU2014264445A1 (en) 2016-01-07
KR20160032013A (ko) 2016-03-23
CN105451740A (zh) 2016-03-30
KR102162038B1 (ko) 2020-10-06
JP6346269B2 (ja) 2018-06-20
RU2686325C2 (ru) 2019-04-25
CA2912203C (en) 2021-08-17
JP2016524602A (ja) 2016-08-18
MX2015015582A (es) 2016-08-11
EP2994137B1 (en) 2022-12-14
US20160106832A1 (en) 2016-04-21
US20180207263A1 (en) 2018-07-26
AU2014264445B2 (en) 2019-08-15
RU2015152785A (ru) 2017-06-16
US9895438B2 (en) 2018-02-20
US20230390388A1 (en) 2023-12-07

Similar Documents

Publication Publication Date Title
CN105451740B (zh) 用纳曲酮治疗癌症
JP6902040B2 (ja) 免疫チェックポイント阻害剤の効力を増強する方法
US12144807B2 (en) Priming of cancer cells with low dose naltrexone
US9782400B2 (en) Oncogenic ROS1 and ALK kinase inhibitor
AU2015101722A4 (en) Oncogenic ros1 and alk kinase inhibitor
US20130280264A1 (en) Total and Phosphorylated IL-1 Receptor-Associated Kinase-1 and IL-1 Receptor-Associated Kinase-4 as a Biomarker for Cancer Progression and Chemotherapy Resistance
JP6558757B2 (ja) 抗腫瘍剤
Gowhari Shabgah et al. A comprehensive review of chemokine CXC17 (VCC1) in cancer, infection, and inflammation
JP2015214579A (ja) 癌細胞アポトーシス
Liu et al. Implication of myeloid differentiation factor 88 inhibitor TJ‐M2010‐5 for therapeutic intervention of hepatocellular carcinoma
NZ714999B2 (en) Treatment of cancer with naltrexone
Di Grazia et al. Rafoxanide Induces Immunogenic Death of Colorectal Cancer Cells.
Janji et al. Emerging role of hypoxia-induced autophagy in cancer immunotherapy
Pandyra Novel immunological mechanisms of targeting tumors and their micro-environment
AU2016101467A4 (en) Alk kinase inhibitor and its use
Sharmeen et al. Gastrointestinal stromal tumor in the rectum
KR20140102811A (ko) 이미퀴모드를 포함하는 항암 치료 보조용 약학 조성물
KR20090090460A (ko) 이미다조퀴놀린을 함유하는 대장암 항암제 및 방사선항암치료 보조제
KR20200124661A (ko) 종양 성장을 감소시키기 위한 미나프린의 용도
TW201909894A (zh) 包含血管破壞劑及免疫查核點抑制劑之用於預防或治療癌症的組合物
Cheon et al. CS07-5. Loss of p53 increases unphosphorylated STAT1, which induces resistance to DNA damage in cancer cells
Costa-Pereira et al. CS07-6. A Novel Requirement for Janus Kinases as Mediators of Drug Resistance Induced by Fibroblast Growth Factor-2 in Human Cancer Cells
JPWO2014200116A1 (ja) がん治療用医薬組成物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP02 Change in the address of a patent holder
CP02 Change in the address of a patent holder

Address after: England Atsushi

Patentee after: LDN Pharmaceutical Co.,Ltd.

Address before: Hakuhoku County, England

Patentee before: LDN Pharmaceutical Co.,Ltd.

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20200929

Address after: Hakuhoku County, England

Patentee after: LDN Pharmaceutical Co.,Ltd.

Address before: England Atsushi

Patentee before: Cancer Vaccine Institute